The U.S. Food and Drug Administration (FDA) approved on Aug. 7 a new medication that lasts longer and requires fewer doses for treating Parkinson’s Disease, potentially offering patients significant relief from the disease’s debilitating symptoms.
The new formulation is an oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release (IR) granules and extended-release (ER) pellets.
Comentarios